The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMW 2021 | Treatment-free intervals: what is best for patients?
Phil McCarthy, MD, of the Roswell Park Comprehensive Cancer Center, Buffalo, NY, talks on the advantages an limitations of giving patients with myeloma treatment-free intervals. Dr McCarthy reports that treatment-free intervals should not be given until it can be accurately identified which patients can stop therapy without negative impacts. It has been shown that patients who receive a fixed duration of maintenance therapy have earlier progressions after stem cell transplantation, and that in transplant ineligible populations the continuation of therapy is associated with superior progression-free survival. Highlighting data from clinical trials, Dr McCarthy explains that this progression-free survival can translate into overall survival, suggesting that the preferred method of drug administration should be that of fixed duration with no treatment-free intervals. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Phil McCarthy, MD, has participated in consultancy work for BlueBird Biotech, Bristol-Myers Squibb, Celgene, Fate Therapeutics, Janssen, Juno, Karyopharm, Magenta Therapeutics, Oncopeptides, Sanofi and Takeda; has received honoraria from BlueBird Biotech, Bristol-Myers Squibb, Celgene, Fate Therapeutics, Janssen, Juno, Karyopharm, Magenta Therapeutics, Medscape, Oncopeptides and Takeda; and has received institutional research grant support from Celgene.
